CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,990 | -20.8% | 7,909 | -2.1% | 0.31% | -1.0% |
| Q2 2023 | $453,331 | +21.7% | 8,075 | -2.0% | 0.31% | -0.6% |
| Q1 2023 | $372,650 | +11.7% | 8,239 | +0.4% | 0.32% | +14.1% |
| Q4 2022 | $333,533 | -37.9% | 8,205 | -0.2% | 0.28% | -51.5% |
| Q3 2022 | $537,000 | +4.7% | 8,218 | -2.6% | 0.57% | +42.8% |
| Q2 2022 | $513,000 | -19.6% | 8,435 | +41.9% | 0.40% | -5.7% |
| Q3 2021 | $638,000 | -35.9% | 5,943 | -3.3% | 0.42% | -30.0% |
| Q2 2021 | $996,000 | -68.7% | 6,148 | +8097.3% | 0.61% | +20100.0% |
| Q1 2020 | $3,181,000 | -30.4% | 75 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $4,568,000 | +788.7% | 75 | -99.1% | 0.00% | -98.6% |
| Q1 1987 | $514,000 | – | 8,192 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |